• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.

作者信息

Agewall Stefan

机构信息

Institute of Clinical Sciences, Karolinska Institute of Danderyd, Stockholm, Sweden.

出版信息

Eur Heart J Cardiovasc Pharmacother. 2025 Jul 7;11(4):319-320. doi: 10.1093/ehjcvp/pvaf039.

DOI:10.1093/ehjcvp/pvaf039
PMID:40574526
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12231122/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a56/12231122/d1f8d084df51/pvaf039il1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a56/12231122/d1f8d084df51/pvaf039il1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8a56/12231122/d1f8d084df51/pvaf039il1.jpg

相似文献

1
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists.关于钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂，我们还有很多需要了解的。
Eur Heart J Cardiovasc Pharmacother. 2025 Jul 7;11(4):319-320. doi: 10.1093/ehjcvp/pvaf039.
2
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
3
Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus: a network meta-analysis of population-based cohort studies.在 2 型糖尿病患者中使用二肽基肽酶-4 抑制剂、胰高血糖素样肽-1 受体激动剂或钠-葡萄糖共转运蛋白-2 抑制剂与骨折风险的关系：基于人群队列研究的网络荟萃分析。
Front Endocrinol (Lausanne). 2024 Oct 11;15:1410883. doi: 10.3389/fendo.2024.1410883. eCollection 2024.
4
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.胰高血糖素样肽-1受体激动剂与钠/葡萄糖协同转运蛋白2抑制剂在预防2型糖尿病合并慢性肾脏病患者慢性肾衰竭及死亡方面的比较疗效
Am J Kidney Dis. 2025 Apr 29. doi: 10.1053/j.ajkd.2025.03.016.
5
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter 2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, and Sulfonylureas for Sight-Threatening Diabetic Retinopathy.胰高血糖素样肽-1 受体激动剂、钠-葡萄糖协同转运蛋白 2 抑制剂、二肽基肽酶-4 抑制剂和磺脲类药物治疗威胁视力的糖尿病视网膜病变的疗效比较。
Ophthalmol Retina. 2024 Oct;8(10):943-952. doi: 10.1016/j.oret.2024.05.003. Epub 2024 May 11.
6
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.二肽基肽酶-4 抑制剂、胰高血糖素样肽 1 受体激动剂和钠-葡萄糖共转运蛋白 2 抑制剂用于心血管疾病患者：一项网状荟萃分析。
Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650. doi: 10.1002/14651858.CD013650.pub2.
7
Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study.2型糖尿病患者中使用钠-葡萄糖协同转运蛋白2抑制剂、二肽基肽酶4抑制剂或胰高血糖素样肽1激动剂后新发外周动脉疾病的比较：一项基于人群的队列研究。
J Am Heart Assoc. 2025 Jun 3;14(11):e034175. doi: 10.1161/JAHA.123.034175. Epub 2025 May 22.
8
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.
9
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline.钠-葡萄糖协同转运蛋白 2 抑制剂或胰高血糖素样肽-1 受体激动剂治疗 2 型糖尿病成人患者：临床实践指南。
BMJ. 2021 May 11;373:n1091. doi: 10.1136/bmj.n1091.
10
Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with kidney outcomes in patients with type 2 diabetes: A systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂、胰高血糖素样肽 1 激动剂和二肽基肽酶 4 抑制剂与 2 型糖尿病患者肾脏结局的关系：系统评价和网络荟萃分析。
PLoS One. 2022 Apr 14;17(4):e0267025. doi: 10.1371/journal.pone.0267025. eCollection 2022.

本文引用的文献

1
Management of dyslipidaemia in patients with comorbidities: facing the challenge.合并症患者血脂异常的管理：应对挑战。
Eur Heart J Cardiovasc Pharmacother. 2024 Nov 6;10(7):608-613. doi: 10.1093/ehjcvp/pvae058.
2
Pharmacological management of transthyretin amyloid cardiomyopathy: a scoping review.转甲状腺素蛋白淀粉样心肌病的药物治疗：范围综述。
Eur Heart J Cardiovasc Pharmacother. 2024 Oct 4;10(6):547-556. doi: 10.1093/ehjcvp/pvae044.
3
2023 ESC Guidelines for the management of cardiomyopathies.2023年欧洲心脏病学会心肌病管理指南。
Eur Heart J. 2023 Oct 1;44(37):3503-3626. doi: 10.1093/eurheartj/ehad194.
4
Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study.钠-葡萄糖共转运蛋白 2 抑制剂与胰高血糖素样肽-1 受体激动剂和 2 型糖尿病患者院外心脏骤停的比较：一项全国性巢式病例对照研究。
Eur Heart J Cardiovasc Pharmacother. 2023 Jul 29;9(5):437-443. doi: 10.1093/ehjcvp/pvad033.
5
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022.2022年的新型药理学药物与心血管药物治疗新策略
Eur Heart J Cardiovasc Pharmacother. 2023 May 11;9(4):353-70. doi: 10.1093/ehjcvp/pvad034.
6
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines.他汀类药物预防接受蒽环类药物治疗的高心脏毒性风险的癌症患者早期心脏功能障碍。
Eur Heart J Cardiovasc Pharmacother. 2023 Sep 20;9(6):515-525. doi: 10.1093/ehjcvp/pvad031.
7
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022年欧洲心脏病学会（ESC）与欧洲血液学协会（EHA）、欧洲治疗放射学与肿瘤学协会（ESTRO）以及国际心脏肿瘤学会（IC-OS）合作制定的心脏肿瘤学指南。
Eur Heart J Cardiovasc Imaging. 2022 Sep 10;23(10):e333-e465. doi: 10.1093/ehjci/jeac106.
8
Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2 抑制剂在 2 型糖尿病患者中的应用与心原性猝死和全因死亡风险。
Eur Heart J Cardiovasc Pharmacother. 2022 Dec 15;9(1):18-25. doi: 10.1093/ehjcvp/pvac043.
9
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
J Am Coll Cardiol. 2022 May 3;79(17):e263-e421. doi: 10.1016/j.jacc.2021.12.012. Epub 2022 Apr 1.
10
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂与有无心力衰竭病史患者的心血管结局：一项系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2022 Sep 3;8(6):557-567. doi: 10.1093/ehjcvp/pvac001.